Richard M. Stone, MD, discusses the promise of menin inhibitors in patients with acute myeloid leukemia.
Richard M. Stone, MD, chief of staff, director of translational research of the Adult Leukemia Program, and institute physician at Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, discusses the promise of menin inhibitors in patients with acute myeloid leukemia (AML).
Presentations from Syndax Pharmaceuticals, Inc. delivered at the 2020 AACR Virtual Annual Meeting and from Kura Oncology at the 2020 ASH Annual Meeting & Exposition described early data with menin inhibitors, according to Stone. Ongoing clinical research indicates that menin inhibitors are promising molecules, Stone says.
For example, one set of data from a preclinical model have demonstrated that menin inhibitors can elicit profound responses in leukemias that are based on mixed lineage leukemia–rearranged AML or myeloid neoplasm–mutant AML. Although ongoing trials do not restrict enrollment to patients with either AML subtype, they appear to be the target patient population for these agents, Stone concludes.